Despite the recent advances in regeneration medicine based on reprogramming approach, I find this paper impressive, because the methods employed in it are free of the concern about potential tumorigenicity.
See also here.
This paper describes a method dispensing with the Myc-retrovirus.
Sickle-cell anemic mice treated with induced pluripotent stem (iPS) cells didn’t develop tumors after three months of the transplant. So I wish to raise the following question:
Is iPS cell method appropriate for the treatment of human disease(s)?
I wish to raise another question:
OK…. Let us watch for progress in iPS cell research.
Unfortunately, in chimeric experiments in mice, c-Myc induces tumors in ca. 20% of subsequent offspring.
Plasmid-induced iPS cells have been reported.
Who will be the first to succeed in cell transplantation?
By the way, common marmoset model seems promising.
Addendum tertium decimum: